Efficacy of daratumumab combination regimen in patients with multiple myeloma: A combined analysis of phase III randomized controlled trials

Autor: Thura W. Htut, Kyaw Z. Thein, Alastair Lawrie, Jane Tighe, Gavin Preston

Publikováno v: eJHaem, Vol 1, Iss 1, Pp 262-266 (2020)

Abstract The use of the CD38 monoclonal antibody daratumumab in combination with standard myeloma chemotherapy regimens has been studied extensively in recent years. We undertook an updated meta‐analysis of phase III randomized controlled trials (R

Externí odkaz: https://doaj.org/article/383c872cf44548b1929ff7f96cee933d

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Autor: Talha Munir, Alexandra Pitchford, Adrian Bloor, Andrew Pettitt, Piers E.M. Patten, Francesco Forconi, Anna Schuh, Christopher P Fox, Simona Gatto, Ben Kennedy, John Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Dena Howard, Anna Hockaday, David Cairns, Sharon Jackson, Natasha Greatorex, Nichola McWhirter, Jane Shingles, Kate Cwynarski, Shankara Paneesha, David Allsup, Andrew Rawstron, Peter Hillmen

Publikováno v: Blood. 140:231-233

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7fe85f55e9f896e126a489cbfa6db36
https://doi.org/10.1182/blood-2022-170463

Timing of high dose methotrexate CNS prophylaxis in DLBCL:a multicenter international analysis of 1,384 patients

Autor: Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J. M. Ferreri, Kate Cwynarski, Pamela McKay

Publikováno v: Wilson, M R, Eyre, T A, Kirkwood, A A, Wong Doo, N, Soussain, C, Choquet, S, Martinez-Calle, N, Preston, G, Ahearne, M J, Schorb, E, Moles-Moreau, M-P, Ku, M, Rusconi, C, Khwaja, J, Narkhede, M, Lewis, K L, Calimeri, T, Durot, E, Renaud, L, Øvlisen, A K, Mcilroy, G, Ebsworth, T J, Elliot, J, Santarsieri, A, Ricard, L, Shah, N, Liu, Q, Zayac, A S, Vassallo, F, Lebras, L, Roulin, L, Lombion, N, Manos, K, Fernandez, R, Hamad, N, Lopez-Garcia, A, O'Mahony, D, Gounder, P, Forgeard, N, Lees, C, Agbetiafa, K, Strüessmann, T, Htut, T W, Clavert, A, Scott, H, Guidetti, A, Barlow, B R, Tchernonog, E, Smith, J, Miall, F, Fox, C P, Cheah, C Y, El Galaly, T C, Ferreri, A J M, Cwynarski, K & McKay, P 2022, ' Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients ', Blood, vol. 139, no. 16, pp. 2499-2511 . https://doi.org/10.1182/blood.2021014506

Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906a66418f9b1bfafd3fd14b33943dce
https://vbn.aau.dk/da/publications/4c8d4993-b73b-4f50-a5d0-8e283e951137

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)

Autor: Nishanthan Rajakumaraswamy, Huseini Kagdi, Gavin Preston, Adam P Cursley, Guan Xing, Christopher Fegan, Toby A. Eyre, Toby Nicholson, Lin Gu, Amin Islam, Heribert Ramroth, Harry W Smith

Publikováno v: British journal of haematology. 194(1)

Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2a40eadec575639670e5828f7dd939
https://pubmed.ncbi.nlm.nih.gov/34128228

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery

Autor: Thomas Creasey, Nimish Shah, Jeremy Schofield, Kate Cwynarski, Matthew R. Wilson, Jeffery Smith, Toby A. Eyre, Cheuk Kie Cheung, Fiona Miall, Kim Linton, Katrina Parsons, Christopher P. Fox, Gavin Preston, Pamela McKay, Matthew J. Ahearne, Matthew A. Timmins, Almurtadha Mula Kh, Jahanzaib Khwaja, Nicolas Martinez-Calle, Johnathon Elliot

Publikováno v: Blood Adv
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421

High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to intercalate HD-MT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a2409dbd0bd720cf92cdf284785ac8
https://pubmed.ncbi.nlm.nih.gov/32761231